Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232944 · ClinicalTrials.gov registry record
Personalized CRT - MPP Post Approval Study
A clinical trial, sponsored by Medtronic.
- Completed
- Registry status
- 1,338
- Enrollment target
NCT03232944 is a clinical trial that has completed, run by Medtronic. The registered enrollment target is 1,338 participants.
The verdict
NCT03232944 has completed, sponsored by Medtronic.
- COMPLETED
- Registry status
- 1,338 participants
- Enrollment target
Study Summary
The purpose of this Post-Approval Study (PAS) is to evaluate the effectiveness of MPP to improve CRT response in the non-responder patient population when used in "real-world" clinical practice, following commercial release. This evaluation is based on the Clinical Composite Score which summarizes the proportions and frequencies of CRT non-responder patients who are "improved", "unchanged" or "worsened" after receiving MPP therapy. Patients will be followed for the duration of the PAS. This study is required by FDA as a condition of approval of the MPP feature and is integrated within the Product Surveillance Registry (PSR).
Interventions
- DEVICE Cardiac Resynchronization Therapy - MPP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,338 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2021-01-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03232944
The ClinicalTrials.gov registry entry for NCT03232944 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cardiac Resynchronization Therapy - MPP is the first listed.
NCT03232944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03232944 about?
NCT03232944 is a clinical study titled "Personalized CRT - MPP Post Approval Study". The purpose of this Post-Approval Study (PAS) is to evaluate the effectiveness of MPP to improve CRT response in the non-responder patient population when used in "real-world" clinical practice, following commercial release. This evaluation is based on the Clinical Composite Score which summarizes t...
What is the current status of trial NCT03232944?
This trial is currently completed. The enrollment target is 1,338 participants. The study started on 2017-07-05. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT03232944?
The interventions under investigation include: Cardiac Resynchronization Therapy - MPP (DEVICE).
Who is sponsoring clinical trial NCT03232944?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.